Literature DB >> 10188898

Competing risks analyses for recurrence from primary breast cancer.

J W Chapman1, E B Fish, M A Link.   

Abstract

The effects of prognostic factors on local, regional or distant metastasis are standardly assessed separately. Competing risks analyses may be used to assess simultaneously the effects of factors on different types of first recurrence. Data for a cohort of 678 primary invasive breast cancer patients accrued between 1971 and 1990, updated to 1995, included type of first recurrence (local, regional, distant). We investigated the effects of the traditional factors of age, tumour size, nodal status, ER, PgR, adjuvant therapy (hormones, chemotherapy, radiotherapy) on type of recurrence and time to recurrence for all patients and for those aged > or = 65. For all ages of patients, there were five factors with significant associations with type or time to first recurrence. Adjuvant radiation was the only factor which had an effect (P < or = 0.05) on the type of first recurrence: being associated with a reduction in local recurrence. Age, nodal status, tumour size and adjuvant chemotherapy all had significant associations across all types of first recurrence, and in particular with time to recurrence for both local and distant metastasis. This indicates a potential lack of independence in these end-points. For patients > or = 65 years of age, there were no factors which differentially affected type of recurrence, while only nodal status and tumour size had significant associations with time to recurrence. Analyses were used to assess simultaneously the effects of traditional prognostic factors and treatment options on type of first recurrence and time to first recurrence. The extension to evaluations with newer prognostic factors would expedite the determination and mode of biologic activity for such factors.

Entities:  

Mesh:

Year:  1999        PMID: 10188898      PMCID: PMC2362724          DOI: 10.1038/sj.bjc.6690240

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  A qualitative discrepancy between censored data rank tests.

Authors:  R L Prentice; P Marek
Journal:  Biometrics       Date:  1979-12       Impact factor: 2.571

2.  Proliferative rate by S-phase measurement may affect cure of breast carcinoma.

Authors:  J W Gamel; J S Meyer; M A Province
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

3.  Parametric survival analysis of adjuvant therapy for stage II breast cancer.

Authors:  J W Gamel; R L Vogel; P Valagussa; G Bonadonna
Journal:  Cancer       Date:  1994-11-01       Impact factor: 6.860

4.  Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone.

Authors:  J W Chapman; W Hanna; H J Kahn; H L Lickley; J Wall; E B Fish; D R McCready
Journal:  Surg Oncol       Date:  1996 Oct-Dec       Impact factor: 3.279

5.  Improved methodology for analyzing local and distant recurrence.

Authors:  R Gelman; R Gelber; I C Henderson; C N Coleman; J R Harris
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

6.  Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the Cancer Registry of Norway.

Authors:  L E Rutqvist; A Wallgren; B Nilsson
Journal:  Cancer       Date:  1984-04-15       Impact factor: 6.860

7.  Competing causes of death for primary breast cancer.

Authors:  E B Fish; J A Chapman; M A Link
Journal:  Ann Surg Oncol       Date:  1998-06       Impact factor: 5.344

8.  Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events.

Authors:  U Veronesi; E Marubini; M Del Vecchio; A Manzari; S Andreola; M Greco; A Luini; M Merson; R Saccozzi; F Rilke
Journal:  J Natl Cancer Inst       Date:  1995-01-04       Impact factor: 13.506

  8 in total
  3 in total

1.  A joint model for multistate disease processes and random informative observation times, with applications to electronic medical records data.

Authors:  Jane M Lange; Rebecca A Hubbard; Lurdes Y T Inoue; Vladimir N Minin
Journal:  Biometrics       Date:  2014-10-15       Impact factor: 2.571

2.  Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysis.

Authors:  O U Ataman; S M Bentzen; M I Saunders; S Dische
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

3.  Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries.

Authors:  Patricia Tai; Edward Yu; Vincent Vinh-Hung; Gábor Cserni; Georges Vlastos
Journal:  BMC Cancer       Date:  2004-09-02       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.